Sequence of Radiation and Targeted Therapy in Brain Metastases

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Completed

Conditions: The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases

Study type: Observational

Funder types: Other

Identifiers

NCT04832672

NCC-005269

Details and patient eligibility

About

The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.

Enrollment: 570 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Had histologically proven primary cancer.
• Had newly diagnosed brain metastases in contrast-enhanced MRI.
• Brain metastases focus should be measurable.
• All the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors.
• Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases.

Exclusion criteria

• Patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail
• Patients with leptomeningeal metastases at first diagnosis.
• Had synchronous or metachronous malignancies that might affect survival.
• Had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures.
• Had incomplete sociodemographic and/or clinicopathologic baseline data

Trial design

570 participants in 2 patient groups

The upfront radiotherapy group

The upfront targeted-therapy group